[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shiraz University of Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100612487","phase-4-rosuvastatin-for-prevention-of-anthracycline-induced-cardiac-dysfunction-in-breast-cancer-patients-100612487",false,"NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use","FEMALE","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[27,28,29,30],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Anthracycline-induced Cardiotoxicity",[32,33,34,35,36,37,38,39,40],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","cardiotoxicity","chemotherapy","anthracycline","NOT_YET_RECRUITING","2025-12-03",{"date":44,"type":45},"2025-12-10","ACTUAL",{"date":47,"type":21},"2026-02-01",{"date":49,"type":21},"2028-04-21",{"name":51,"class":52},"Shiraz University of Medical Sciences","OTHER",7,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100591361","ctffr-and-prediction-of-non-significant-cad-lesions-100591361","NCT06979427","CTFFR and Prediction of Non-Significant CAD Lesions","Evaluation of the Ability of CTFFR to Determine Non-significant Lesions of Coronary Disease Based on MACE in One-year Follow-up of Patients (Seeing Beyond the Stenosis: CTFFR and MACE in a One-Year Follow-Up)","Inclusion Criteria:\n\n* Patients were enrolled if they had at least one intermediate coronary lesion (classified as 50-70% diameter stenosis on visual judgment) on CCTA and then underwent FFR testing\n\nExclusion Criteria:\n\n* Patients having past coronary artery bypass graft surgery (CABG)\n* previous PCI in the target vascular\n* significant renal impairment define with eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* contrast allergy\n* poor image quality that prevented appropriate CCTA or CT-FFR analysis","ALL","20 Years","80 Years",{"count":65,"type":21},250,[67],"NA","In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography (CCTA) with NiFFR assessment. Patients were followed for one year to monitor for MACE",[70],"Chronic Coronary Syndrome",[70,72,73,74],"Major adverse coronary events (MACE)","fractional flow reserve","coronary CT angiography","RECRUITING","2025-05-18",{"date":78,"type":45},"2025-05-21",{"date":80,"type":45},"2024-01-01",{"date":82,"type":21},"2026-09-01",{"name":51,"class":52},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100555269","phase-4-ticagrelore-alone-post-pci-100555269","NCT06509893","Ticagrelore Alone Post PCI","A Single-center, Randomized, 6-month, Non-inferiority Study to Compare the Safety and Efficacy of TICAgreLor mONotherapy Versus Dual Antiplatelet Therapy in Chronic Coronary Syndrome Patients Post Percutaneous Coronary IntErvention (TICALONE)","TICALONE","Inclusion Criteria:\n\n* Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome\n* The patient has provided written informed consent as approved by the ethics committee of the Shiraz University of Medical Sciences.\n\nExclusion Criteria:\n\n* Contraindication to aspirin, clopidogrel, ticagrelor, or any other reason that study drug should not be administered (including hypersensitivity, moderate or severe liver disease, active bleeding, and major surgery within 30 days)\n* Atrial fibrillation or other indication for oral anticoagulant therapy.\n* Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices (cyclosporine, and quinidine), or strong CYP3A inducers ( rifampin, rifampicin, phenytoin, and carbamazepine)\n* Females of child-bearing age unless negative pregnancy test at screening and willing to use effective contraception for the duration of trial\n* Females who are breastfeeding at the time of enrolment.\n* Unsuccessful PCI or PCI without optimal stent placement; this decision is made by the supervising interventional cardiologist.\n* patients with anatomical SYNTAX score ≥23 prior to PCI\n* Patients with planned surgical intervention to treat any cardiac or non-cardiac condition.\n* Previous PCI in the last 6 months.\n* Current (same hospitalization) or previous (within 12 months) acute coronary syndrome.\n* History of definite stent thrombosis.\n* Concomitant cardiac valve disease requiring invasive therapy.\n* Acute heart failure.\n* Active myocarditis.\n* Cardiomyopathy.\n* Patient in hemodialysis.\n* History of stroke or transient ischemic cerebrovascular accident.\n* History of intracranial hemorrhage or other intracranial pathology associated with increased bleeding risk.\n* Hemoglobin \\\u003C10 g\u002FdL\n* Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy.\n* Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor.\n* Participation in another trial with an investigational drug or device.\n* Assessment that the subject is not likely to comply with the study procedures or have complete follow-up.\n* Known drug or alcohol dependence within the past 12 months as judged by the investigator.",{"count":94,"type":21},5400,[24],"After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic",[98],"Coronary Artery Disease",[100,101,102,103,104],"Percutaneous coronary intervention","dual antiplatelet therapy","clopidogrel","ticagrelor","MACE","2025-05-16",{"date":78,"type":45},{"date":108,"type":45},"2024-08-01",{"date":110,"type":21},"2026-05-01",{"name":51,"class":52},2,""]